Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes

Kaul, Upendra; Bangalore, Sripal; Seth, Ashok; Arambam, Priyadarshini; Abhaichand, Rajpal K.; Patel, Tejas; Banker, D.; Abhyankar, Atul; Mullasari, Ajit; Shah, Sanjay; Jain, Rashmi; Kumar, Premchand R.; Bahuleyan, C.G.

doi:10.1056/nejmoa1510188

Cited by 110 publications

(55 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, these trials compared CABG against PCI with bare metal stents and first-generation drug-eluting stent (paclitaxel or sirolimus-eluting stents), and findings from recent studies suggest that the superiority of CABG over PCI may be less clear with the use of newer generation drug-eluting stent. [22][23][24] The results from our present analysis provide an insight into the contemporary patterns of revascularization among patients with DM and multivessel CAD in the setting of NSTEMI. We observed greater utilization of PCI versus CABG in this patient population throughout the study period.…”

Section: Discussionmentioning

confidence: 84%

Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction

Pandey

McGuire

Lemos

et al. 2016

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

Background-Current guidelines recommend surgical revascularization (coronary artery bypass graft [CABG]) over percutaneous coronary intervention (PCI) in patients with diabetes mellitus and multivessel coronary artery disease. Few data are available describing revascularization patterns among these patients in the setting of non-ST-segment-elevation myocardial infarction. Methods and Results-Using Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (ACTION Registry-GWTG), we compared the in-hospital use of different revascularization strategies (PCI versus CABG versus no revascularization) in diabetes mellitus patients with non-ST-segment-elevation myocardial infarction who had angiography, demonstrating multivessel coronary artery disease between July 2008 and December 2014. Factors associated with use of CABG versus PCI were identified using logistic multivariable regression analyses. A total of 29 769 patients from 539 hospitals were included in the study, of which 10 852 (36.4%) were treated with CABG, 13 760 (46.2%) were treated with PCI, and 5157 (17.3%) were treated without revascularization. The overall use of revascularization increased over the study period with an increase in the proportion undergoing PCI (45% to 48.9%; P trend =0.0002) and no change in the proportion undergoing CABG (36.1% to 34.7%; p trend =0.88). There was significant variability between participating hospitals in the use of PCI and CABG (range: 22%-100%; 0%-78%, respectively; P value <0.0001 for both). Patient-level, but not hospital-level, characteristics were statistically associated with the use of PCI versus CABG, including anatomic severity of the disease, early treatment of adenosine diphosphate receptor antagonists at presentation, older age, female sex, and history of heart failure. Conclusions-Among patients with diabetes mellitus and multivessel coronary artery disease presenting with non-ST-segment-elevation myocardial infarction, only one third undergo CABG during the index admission. Furthermore, the use of PCI, but not CABG, increased modestly over the past 6 years. (Circ Cardiovasc Qual Outcomes. 2016;9:197-205.

show abstract

Section: Discussionmentioning

confidence: 84%

Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction

Pandey

McGuire

Lemos

et al. 2016

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

show abstract

“…Along this line, a recent randomised trial comparing PCI with EES against CABG for the treatment of left main disease reported similar outcomes for both revascularisation techniques at 3-year follow-up, with very low rates of stent thrombosis (0.7%) 39. The superiority of limus-based, new-generation DES for parameters of both efficacy and safety has been also established in patients with diabetes, for whom a benefit of PES was initially postulated 40. Moreover, new-generation DES represent the most effective therapy for the treatment of in-stent restenosis with a difference in diameter stenosis of about 10% at angiographic follow-up when compared against drug-coated balloons 41.…”

Section: Introductionmentioning

confidence: 92%

From bare metal to barely anything: an update on coronary stenting

Piccolo

Franzone

Windecker

2017

Heart

View full text Add to dashboard Cite

“…Одна из последних публикаций посвящена сравнению результатов имплан-тации стентов PES и EES у больных с СД (TUXEDO trial, 2015). При использовании PES у больных СД в течение года наблюдения отмечены существенно и достоверно более высокая частота развития спонтанных ИМ, тром-боза стента, повторных таргетных реваскуляризаций, причем результаты не зависели от того, получает ли па-циент инсулин [21].…”

Section: сахарный диабет Diabetes Mellitusunclassified

Myocardial revascularization in patients with type 2 diabetes mellitus: An overview of modern techniques

Golukhova¹,

Kuznetsova²

2016

Diabetes mellitus

View full text Add to dashboard Cite

КардиологияCardiology сновной причиной летальности в мире про-должают оставаться сердечно-сосудистые за-болевания (ССЗ). По данным Всемирной Организации Здравоохранения, ежегодно от сердечно-сосудистых заболеваний умирают около 17 млн человек, что составляет 29% от всех случаев смерти в мире [1].Многочисленные исследования показали, что сахар-ный диабет (СД) является независимым фактором риска развития и прогрессирования атеросклероза сосудов и значимо повышает риски развития кардиоваскулярных событий [2,3].По последним данным, численность больных СД в мире за последние 10 лет увеличилась более чем в 2 раза и к концу 2014 г. достигла 387 млн человек [4].Согласно данным Государственного регистра боль-ных СД, на 1 января 2015 г. в России зарегистрировано 4,1 млн случаев (данные на 1 января 2014 -3,9 млн), из них число больных СД 2 типа (CД2) составило 3,7 млн [5]. Между тем, по данным эпидемиологических исследований, выполненных в период 2002-2010 гг. в ФГБУ «Эндокринологический научный центр» МЗ, истинная распространенность данного заболевания в 3-4 раза была выше официально зарегистрированного числа больных и достигала 9-10 млн случаев, что со-ставляет около 7% населения. СД в 4 раза увеличивает риск развития ишемической болезни сердца (ИБС) и об-уславливает три четверти связанных с диабетом леталь-ных исходов [2]. У больных ИБС и СД часто выявляется Реваскуляризация миокарда у больных ИБС в сочетании с сахарным диабетом 2 типа: обзор современных технологий © Голухова Е.З., Кузнецова Е.В. ФГБУ

show abstract

Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes

Cited by 110 publications

References 16 publications

Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction

Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non–ST Elevation Myocardial Infarction

From bare metal to barely anything: an update on coronary stenting

Myocardial revascularization in patients with type 2 diabetes mellitus: An overview of modern techniques

Contact Info

Product

Resources

About